Welcome to our dedicated page for Lobe Sciences news (Ticker: LOBEF), a resource for investors and traders seeking the latest updates and insights on Lobe Sciences stock.
Lobe Sciences Ltd. reports news as a clinical-stage biopharmaceutical company that acquires preclinical and early-stage therapeutic assets and advances them through focused subsidiaries. Its development model centers on formulation work, intellectual property protection, regulatory engagement, and program-specific funding structures.
Recurring updates include progress for Cynaptec Pharmaceuticals' L-130 program and Applied Lipid Technologies' S-100 program, including disease areas such as chronic cluster headache and sickle cell disease. Company news also covers financial results, private placements, working-capital actions, investor relations engagements, healthcare conference participation, and public-company governance changes.
Lobe Sciences (OTCQB:LOBEF) announced that CEO Dr. Frederick D. Sancilio will attend the D. Boral Capital Global Conference on May 7, 2026 at The Plaza Hotel in New York to meet institutional investors, pharma companies, and strategic partners.
The company highlighted its two lead programs: L-130 (psilocin mucate), advanced by Cynaptec (Lobe owns 64%), and S-100, which is completing CMC work ahead of a planned Phase 2a study.
Lobe Sciences (OTCQB:LOBEF) reported Q2 2026 interim results and operational progress. Cash was $1,071,199 with short-term investments of $3,889,632 and net working capital of $2,160,073. R&D for the six months was $2,115,338; operating cash used was $2,637,862. Net loss for the quarter was $3,693,896. The company advanced two core programs (L-130 for chronic cluster headache and S-100 for sickle cell disease) and completed a non-brokered private placement raising approximately $950,000.
Lobe Sciences (OTCQB:LOBEF) commented on the White House April 2026 Executive Order endorsing expanded research into neurological and mental health treatments. The company said the action could enable study of compounds by safety and clinical potential rather than historical scheduling. Lobe highlighted its subsidiary Cynaptec and drug candidate L-130, being developed as a non-hallucinogenic candidate for chronic cluster headache and substance use disorder.
Lobe Sciences (OTCQB:LOBEF) engaged Massive Intelligence Pty Ltd for investor relations and corporate communications under a letter dated April 15, 2026.
The initial engagement is for three months from April 15, 2026 for a total cash retainer of US$11,800; an optional six-month renewal would add US$31,500. No securities will be issued in connection with the engagement.
Lobe Sciences (OTCQB:LOBEF) closed a non-brokered private placement of 14,615,384 common shares at $0.065 per share for aggregate gross proceeds of approximately $950,000 on April 20, 2026.
Proceeds will fund working capital, advance the S-100 drug candidate for sickle cell disease, and provide capital to subsidiary Applied Lipid Technologies to support development toward human clinical trials; the company has procured required active pharmaceutical ingredient. Securities are subject to a four-month Canadian hold period and are not registered in the United States.
Lobe Sciences (OTCQB:LOBEF) announced a non-brokered private placement of 14,615,384 common shares at $0.065 per share for aggregate gross proceeds of approximately $950,000 on April 10–11, 2026.
The company said proceeds will fund working capital and general corporate expenses; the placement is subject to regulatory approvals, a four-month Canadian hold period, and securities are not registered for sale in the United States.
Lobe Sciences (OTCQB:LOBEF) reported a materially improved financial position as of March 25, 2026. Liabilities fell ~81% from $2.35M to $0.44M; cash rose from $0.24M to $5.99M; net working capital improved by $6.1M to $4.05M; outstanding warrants fell ~70% to ~13M. The company adopted a subsidiary-based, capital-efficient model and sold a 34% interest in Cynaptec to strengthen runway and reduce dilution risk.
Management converted most convertible notes into equity on favorable terms and noted the recent audit omitted a going-concern explanatory paragraph.
Lobe Sciences (OTCQB:LOBEF, CSE:LOBE) announced the promotion of Mr. Mirza Rahimani to Chief Financial Officer, effective March 2, 2026. Mr. Rahimani joined the company December 1, 2025 as a financial advisor and brings over 15 years of experience in accounting, financings, M&A and public-company reporting under IFRS and US GAAP.
He succeeds Mr. Yong Yao, who previously served as CFO through an arrangement with Century Biolabs. The change is presented as part of management alignment to support strategic transactions and regulatory compliance.
Lobe Sciences (OTCQB:LOBEF) announced that CEO Dr. Frederick D. Sancilio will be in Miami, Florida during the Jefferies and Leerink Healthcare Conferences on March 2026 and is available for investor and partner meetings.
The company advances preclinical and early-stage therapeutic assets via focused subsidiaries and is currently progressing two patented programs: L-130 for chronic cluster headache and S-100 for sickle cell disease, with additional programs under evaluation in substance use disorder and other neurological indications.
Lobe Sciences (OTCQB:LOBEF) reported Q1 fiscal 2026 results for the quarter ended November 30, 2025, highlighting increased R&D activity and maintained liquidity. Cash was $5.99M, short-term investments $1.03M, and net working capital $4.05M. R&D rose to $982,087 as L-130 preclinical and regulatory work advanced; net loss was $1.31M. The company reiterated progress via its 64% subsidiary Cynaptec (L-130) and early-stage S-100 program, while noting commercialization and reimbursement uncertainty for a medical food effort in Georgia.